Competitive PositionWith the failure of a competitor's Phase 3 trial in generalized Myasthenia Gravis (gMG), this has positive readthrough to ARGX's Vyvgart, which is already approved for gMG and provided a strong benefit.
Drug Development ProgressARGX announced a 'GO' decision to advance efgartigimod into Phase 3 development in Sjogren's syndrome following encouraging topline results from the Phase 2 RHO trial.
Market OpportunityThe market opportunity for Sjögren's Syndrome is significant, with an estimated 330,000 patients in the US alone, and analysts estimate around $2 billion in peak US sales for Vyvgart, reflecting a substantial commercial potential.